

## Editorial

## 2014 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

Emmanuel J. Favaloro, PhD, FFSc (RCPA)<sup>1</sup>

<sup>1</sup> Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales, Australia

Semin Thromb Hemost 2014;40:407–412.

Welcome to another Eberhard F. Mammen award announcement. As noted previously,<sup>1–3</sup> Thieme, the publisher of *Seminars in Thrombosis & Hemostasis*, has created the Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards in the honor of Dr. Eberhard F. Mammen (► **Fig. 1**), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009 under two categories:

- **Most Popular Article Awards:** Awarded to the authors of the most popular articles published in *Seminars in Thrombosis & Hemostasis*. The awards are determined by the Editor in Chief on the basis of user statistics from Thieme e-Journals from the preceding 2 years. The awards comprise two major cash prizes of US\$1,000 plus “open access” status for these articles thereafter.
- **Young Investigator Awards:** Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis and whose subject matter is determined to be in the spirit of Dr. Mammen. Up to six cash prizes of US\$1,000 are awarded in any year. Awardees are expected to prepare a review or an article related to the topic of their presentation for publication in *Seminars in Thrombosis & Hemostasis*.

Further details of the awards and the award winners are posted online (<<http://www.thieme.com/sth>>), and previous award winner announcements are also available in print.<sup>4–9</sup>

It is, therefore, with great pleasure that we would like to announce the latest winners of the 2014 Eberhard F. Mammen awards for the most popular articles from *Seminars in Thrombosis & Hemostasis* for the period 2012 to 2013 inclusive.



**Fig. 1** Eberhard F. Mammen (1930–2008).

We will be announcing the young investigator awards related to meetings held in the recent past on a later date.

### 2014 “Most Popular” Article Awards

As mentioned, the “most popular” awards are given to the authors of the most popular articles published in *Seminars in Thrombosis & Hemostasis* as determined on the basis of user statistics from the publisher of this journal and covering the preceding 2-year period. Thus, the 2014 “most popular” awards are granted to the most popular articles from 2012 to 2013. However, this year saw the continuing trend to the ongoing presence of many of the previous “most popular” awardees on the STH top 100 listing of most popular articles.

**Address for correspondence**  
Emmanuel J. Favaloro, PhD, FFSc (RCPA), Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales 2145, Australia  
(e-mail: [emmanuel.favaloro@health.nsw.gov.au](mailto:emmanuel.favaloro@health.nsw.gov.au)).

**Issue Theme** An Update on the Thrombotic Microangiopathies Hemolytic Uremic Syndrome (HUS) and Thrombotic Thrombocytopenic Purpura (TTP); Guest Editors, Magdalena Riedl, MD, Dorothea Orth-Höller, MD, and Reinhard Würzner, MD, PhD.

Copyright © 2014 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.  
Tel: +1(212) 584-4662.

DOI <http://dx.doi.org/10.1055/s-0034-1376151>.  
ISSN 0094-6176.

**Table 1** Top 50 downloaded non-open-access articles from *Seminars in Thrombosis & Hemostasis* (2012 and 2013 inclusive)

Rank, articles
1. Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. <i>Semin Thromb Hemost</i> 2012;38(1):47–54
2. Kenet G, Aronis S, Berkun Y, et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. <i>Semin Thromb Hemost</i> 2011;37(7):802–809
3. Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitasking participants in intercellular communication. <i>Semin Thromb Hemost</i> 2012;38(1):102–113
4. Kulkarni R, Soucie JM. Pediatric hemophilia: a review. <i>Semin Thromb Hemost</i> 2011;37(7):737–744
5. Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. <i>Semin Thromb Hemost</i> 2012;38(5):454–462
6. Lyle CA, Bernard TJ, Goldenberg NA. Childhood arterial ischemic stroke: a review of etiologies, antithrombotic treatments, prognostic factors, and priorities for future research. <i>Semin Thromb Hemost</i> 2011;37(7):786–793
7. Schulman S, Majeed A. The oral thrombin inhibitor dabigatran: strengths and weaknesses. <i>Semin Thromb Hemost</i> 2012;38(1):7–15
8. Kadir RA, McIntock C. Thrombocytopenia and disorders of platelet function in pregnancy. <i>Semin Thromb Hemost</i> 2011;37(6):640–652
9. Tan CW, Ward CM, Morel-Kopp MC. Evaluating heparin-induced thrombocytopenia: the old and the new. <i>Semin Thromb Hemost</i> 2012;38(2):135–143
10. Breakey VR, Blanchette VS. Childhood immune thrombocytopenia: a changing therapeutic landscape. <i>Semin Thromb Hemost</i> 2011;37(7):745–755
11. Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. <i>Semin Thromb Hemost</i> 2010;36(8):807–818
12. Jayandharan GR, Srivastava A, Srivastava A. Role of molecular genetics in hemophilia: from diagnosis to therapy. <i>Semin Thromb Hemost</i> 2012;38(1):64–78
13. Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. <i>Semin Thromb Hemost</i> 2012;38(5):433–446
14. Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. <i>Semin Thromb Hemost</i> 2012;38(7):673–682
15. Pels SG. Current therapies in primary immune thrombocytopenia. <i>Semin Thromb Hemost</i> 2011;37(6):621–630
16. Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. <i>Semin Thromb Hemost</i> 2012;38(5):483–496
17. Szántó T, Joutsu-Korhonen L, Deckmyn H, Lassila R. New insights into von Willebrand disease and platelet function. <i>Semin Thromb Hemost</i> 2012;38(1):55–63
18. Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. <i>Semin Thromb Hemost</i> 2012;38(4):305–321
19. Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. <i>Semin Thromb Hemost</i> 2012;38(1):16–22
20. Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. <i>Semin Thromb Hemost</i> 2012;38(2):178–184
21. Favaloro EJ, Wong RC. The antiphospholipid syndrome: diagnosis, pathogenesis, laboratory testing, and management. <i>Semin Thromb Hemost</i> 2012;38(4):299–304
22. Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. <i>Semin Thromb Hemost</i> 2012;38(1):79–94
23. Linden MD, Tran H, Woods R, Tonkin A. High platelet reactivity and antiplatelet therapy resistance. <i>Semin Thromb Hemost</i> 2012;38(2):200–212
24. Coppola A, Tufano A, Di Capua M, Franchini M. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. <i>Semin Thromb Hemost</i> 2011;37(8):929–945
25. Montagnana M, Favaloro EJ, Lippi G. Coffee intake and cardiovascular disease: virtue does not take center stage. <i>Semin Thromb Hemost</i> 2012;38(2):164–177
26. Tsai HM. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. <i>Semin Thromb Hemost</i> 2012;38(5):469–482
27. Scharf RE. Drugs that affect platelet function. <i>Semin Thromb Hemost</i> 2012;38(8):865–883
28. Galli M. Interpretation and recommended testing for antiphospholipid antibodies. <i>Semin Thromb Hemost</i> 2012;38(4):348–352
29. Zoellner H. Dental infection and vascular disease. <i>Semin Thromb Hemost</i> 2011;37(3):181–192
30. Lippi G, Favaloro EJ, Cervellin G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. <i>Semin Thromb Hemost</i> 2011;37(3):237–251
31. Franchini M, Lippi G, Favaloro EJ. Acquired inhibitors of coagulation factors: part II. <i>Semin Thromb Hemost</i> 2012;38(5):447–453
32. Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. <i>Semin Thromb Hemost</i> 2013;39(2):117–126
33. Adams M. Tissue factor pathway inhibitor: new insights into an old inhibitor. <i>Semin Thromb Hemost</i> 2012;38(2):129–134
34. Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. <i>Semin Thromb Hemost</i> 2012;38(4):339–347
35. Köse O, Zimmerhackl LB, Jungraithmayr T, Mache C, Nürnberger J. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. <i>Semin Thromb Hemost</i> 2010;36(6):669–672

**Table 1** (Continued)

Rank, articles
36. Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the "CAPS Registry." <i>Semin Thromb Hemost</i> 2012;38(4):333–338
37. De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. <i>Semin Thromb Hemost</i> 2011;37(3):226–236
38. Thom KE, Hanslik A, Male C. Anticoagulation in children undergoing cardiac surgery. <i>Semin Thromb Hemost</i> 2011;37(7):826–833
39. Bitzan M, Schaefer F, Reymond D. Treatment of typical (enteropathic) hemolytic uremic syndrome. <i>Semin Thromb Hemost</i> 2010;36(6):594–610
40. Flaumenhaft R, Mairuhu AT, Italiano JE. Platelet- and megakaryocyte-derived microparticles. <i>Semin Thromb Hemost</i> 2010;36(8):881–887
41. Ranucci M, Baryshnikova E, Colella D. Monitoring prohemostatic treatment in bleeding patients. <i>Semin Thromb Hemost</i> 2012;38(3):282–291
42. Favaloro EJ. Clinical utility of the PFA-100. <i>Semin Thromb Hemost</i> 2008;34(8):709–733
43. Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. <i>Semin Thromb Hemost</i> 2012;38(1):31–37
44. Toriello HV. Thrombocytopenia-absent radius syndrome. <i>Semin Thromb Hemost</i> 2011;37(6):707–712
45. Schroeder V, Kohler HP. Factor XIII deficiency: an update. <i>Semin Thromb Hemost</i> 2013;39(6):632–641
46. Kuperman AA, Kenet G, Papadakis E, Brenner B. Intraventricular hemorrhage in preterm infants: coagulation perspectives. <i>Semin Thromb Hemost</i> 2011;37(7):730–736
47. Heleen van Ommen C, Middeldorp S. Thrombophilia in childhood: to test or not to test. <i>Semin Thromb Hemost</i> 2011;37(7):794–801
48. Darvish-Kazem S, Douketis JD. Perioperative management of patients having noncardiac surgery who are receiving anticoagulant or antiplatelet therapy: an evidence-based but practical approach. <i>Semin Thromb Hemost</i> 2012;38(7):652–660
49. Franchini M, Vescovi PP, Garofano M, Veneri D. <i>Helicobacter pylori</i> -associated idiopathic thrombocytopenic purpura: a narrative review. <i>Semin Thromb Hemost</i> 2012;38(5):463–468
50. Hellgren M. Hemostasis during normal pregnancy and puerperium. <i>Semin Thromb Hemost</i> 2003;29(2):125–130

Given that these articles are granted "open-access" status as part of the award, this ongoing presence on the most downloaded article listing may be in part due to their free availability in addition to their popularity per se. Also appearing on this 2012–2013 list was another "open-access" article. Since the open-access model of publishing makes articles much more freely available than non-open-access ones, this may generate an inequitable advantage for these in terms of download statistics. Accordingly, the publisher of *Seminars in Thrombosis & Hemostasis* has agreed to establish a separate category of the award for "open-access" articles. Accordingly, for this year and hereafter, the most popular articles will be listed in two separate tables. ►Table 1 lists the top 50 most downloaded non-open-access articles from *Seminars in Thrombosis & Hemostasis* (2012 and 2013 inclusive).<sup>10–59</sup> ►Table 2 lists

the top most downloaded open-access articles from *Seminars in Thrombosis & Hemostasis* (2012 and 2013 inclusive) that appeared in the top 100 download list, including previous winners of this award.<sup>60–66</sup> As previously highlighted in these editorials,<sup>9</sup> previous winners of the award are not eligible for another award for the same article; hence, most of the articles listed in ►Table 2 do not qualify for an award in 2014. The notable exception here is the top-listed article,<sup>60</sup> which was published in 2012, and which has not previously been granted an award, and, hence, certainly qualifies for the 2014 award. The two top-listed articles<sup>10,11</sup> in ►Table 1 are also winners of the 2014 Eberhard F. Mammen award for most popular article ("general category"). Accordingly, the 2014 Eberhard F. Mammen Award winners for most popular article (2012–2013 inclusive) are as follows:

**Table 2** Top downloaded open access articles from *Seminars in Thrombosis & Hemostasis* (2012 and 2013 inclusive)

Rank, articles
1. Salmela B, Joutsu-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. <i>Semin Thromb Hemost</i> 2012;38(1):23–30
2. Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradox." <i>Semin Thromb Hemost</i> 2010;36(1):59–70
3. Rak J. Microparticles in cancer. <i>Semin Thromb Hemost</i> 2010;36(8):888–906
4. Jurk K, Kehrel BE. Platelets: physiology and biochemistry. <i>Semin Thromb Hemost</i> 2005;31(4):381–392
5. Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. <i>Semin Thromb Hemost</i> 2011;37(3):267–274
6. Mariani G, Bernardi F. Factor VII deficiency. <i>Semin Thromb Hemost</i> 2009;35(4):400–406
7. Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. <i>Semin Thromb Hemost</i> 2011;37(3):280–297

### General Category

1. Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. *Semin Thromb Hemost* 2012;38(1):47–54.
2. Kenet G, Aronis S, Berkun Y, et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. *Semin Thromb Hemost* 2011;37(7):802–809.

### Open-Access Category

1. Salmela B, Joutsu-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anti-coagulants: bleeding risk, compliance, and coagulation analysis. *Semin Thromb Hemost*. 2012 Feb;38(1):23–30.

All authors of these award-winning articles were thrilled to hear that their articles had won an Eberhard F. Mammen Most Popular Award and provided the following additional responses.

From Kent Chapman (►**Fig. 2**): “As a scientist who performs ADAMTS-13 [a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13] assays in the laboratory, I came to write this paper not only out of personal interest in the subject matter, but also as a part of the Master’s degree I was enrolled in at the time. I also felt that the literature at the time regarding TTP [Thrombotic Thrombocytopenic Purpura] was lacking a comprehensive review of TMA [Thrombotic Microangiopathies], TTP, and ADAMTS-13 and it was my aim to try and collate all this information in one paper to help others with the understanding of a very complex and often misunderstood disease. I am delighted to receive this award and even more excited to realise that the paper has been as popular as it is.”

Drs. Gili Kenet and Ulrike Nowak-Göttl (►**Fig. 3**), both pediatric hematologists with an interest in childhood hemostasis, provided the following commentary: “Because throm-



**Fig. 2** Kent Chapman.



**Fig. 3** Drs. Gili Kenet (left) and Ulrike Nowak-Göttl (right). The picture was taken in October 2013 in Kiel during the Congress of the Biannual Meeting of the Pediatric Society of Haematology and Immunology chaired by Prof. Nowak-Göttl.

boses and stroke in pediatric patients are rare diseases, conducting scientific studies within a single hospital or even within a single country is difficult. Aiming to gather scientific data and create recommendations that can be applied to a broad spectrum of children over the world we gathered together a large group of collaborators. We have previously chaired the pediatric/perinatal hemostasis scientific standardisation committee (SCC) of the International Society on Thrombosis and Haemostasis (ISTH), promoting international research collaboration and cooperative multicenter studies. The Eberhard Mammen awarded ‘systematic review and meta-analysis on observational studies in children with antiphospholipid antibodies’ is one example published by this international cooperative group and was first presented during the ISTH SSC 2010 meeting in Cairo, Egypt.”

At the present time Prof. Kenet is director of the Thrombosis Unit and National Hemophilia Center in Tel Hashomer affiliated with the Sackler Medical School, Tel Aviv University in Israel, and Prof. Nowak-Göttl is head of the Thrombosis and Hemophilia Treatment Centre, Institute of Clinical Chemistry, at the University Hospital Schleswig-Holstein, Kiel & Lübeck, Germany.

From Birgitta Salmela and Riitta Lassila (►**Fig. 4**): “The 2014 Eberhard F. Mammen ‘Most Popular’ articles award both surprised and delighted our team. At the time we wrote the article, only few practical insights into the topic were available. Therefore, we felt it important to share our clinical experience in view of the available studies. The variable and extensive exclusion criteria used in the clinical trial studies were not easy to find in the literature, methods to measure the anticoagulant effects when necessary were only available as research tools, and the absence of any specific antidotes raised serious concerns. As we encountered patients in need of urgent surgery or with new thrombosis while on new direct oral anticoagulant treatment, we felt it imperative to learn more about the field and to share our experience. Winning this award encourages us to continue to





**Fig. 4** From left to right: Drs. Lotta Joutsen-Korhonen, Elina Armstrong, Birgitta Salmela, and Riitta Lassila. Photo taken at Helsinki University Central Hospital.

be active in improving patient care, collaborate with our colleagues and to follow the field of new and developing anticoagulants. We are honored to be acknowledged in this way and look forward to reading the excellent articles appearing in *Seminars in Thrombosis & Hemostasis* in the future."

It is also interesting (as always) to reflect on some of the other most popular articles, which relate to a variety of topics within the field of thrombosis and hemostasis. Of some continued interest, and analogous to previous years, is that (1) some articles from previous most popular award listings have appeared yet again (► **Table 2**), and this highlights their perpetuating interest to our readership, and (2) that many are from previous young investigator award winners (► **Table 1**).<sup>12,21,24,26,52</sup> Indeed, what I find personally gratifying is that every young investigator award winner from 2010 (as announced in 2011)<sup>7</sup> is listed in either ► **Table 1** or ► **Table 2**,<sup>12,21,26,52,60</sup> and also that every one of these articles also appeared within last year's top 100 listing. Also interesting is that a few articles on the top 50 listing (► **Table 1**), included as authors, individuals who were later to be awarded a young investigator award,<sup>10,15,20,49</sup> including one of the winners of the current "most popular" article

award.<sup>10</sup> These findings would appear to more than validate the young investigator award process, and I look forward to seeing their careers continue to develop.

I would like, as always, to thank not only all the authors listed in ► **Tables 1** and **2** but also the contributing authors who did not manage to make these listings, as well as all the guest editors of issues recently published in *Seminars in Thrombosis & Hemostasis*. I look forward to seeing next year's listing!

## References

- 1 Favaloro EJ. Editorial. Welcome to a special issue of *Seminars in Thrombosis and Hemostasis*—the closing issue for 2008. *Semin Thromb Hemost* 2008;34:693–696
- 2 Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930–2008). *Semin Thromb Hemost* 2008;34(8):703–707
- 3 Favaloro EJ. Editorial. Welcome to the first issue of *Seminars in Thrombosis and Hemostasis* for 2009. *Semin Thromb Hemost* 2009;35:1–2
- 4 Favaloro EJ. Editorial. Winners of the inaugural Eberhard F. Mammen Award for most popular article. *Semin Thromb Hemost* 2009; 35:587–590
- 5 Favaloro EJ. Editorial. 2009 Eberhard F. Mammen Young Investigator Award winners. *Semin Thromb Hemost* 2010;36: 469–470
- 6 Favaloro EJ. Winners of the 2010 Eberhard F. Mammen award for most popular article during 2008–2009. *Semin Thromb Hemost* 2010;36(7):685–692
- 7 Favaloro EJ. 2011 Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2011;37(5):431–439
- 8 Favaloro EJ. 2012 Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2012;38:425–432
- 9 Favaloro EJ. Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2013;39:567–574
- 10 Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. *Semin Thromb Hemost* 2012;38(1):47–54
- 11 Kenet G, Aronis S, Berkun Y, et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. *Semin Thromb Hemost* 2011;37(7):802–809
- 12 Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitasking participants in intercellular communication. *Semin Thromb Hemost* 2012;38(1):102–113
- 13 Kulkarni R, Soucie JM. Pediatric hemophilia: a review. *Semin Thromb Hemost* 2011;37(7):737–744
- 14 Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. *Semin Thromb Hemost* 2012;38(5):454–462
- 15 Lyle CA, Bernard TJ, Goldenberg NA. Childhood arterial ischemic stroke: a review of etiologies, antithrombotic treatments, prognostic factors, and priorities for future research. *Semin Thromb Hemost* 2011;37(7):786–793
- 16 Schulman S, Majeed A. The oral thrombin inhibitor dabigatran: strengths and weaknesses. *Semin Thromb Hemost* 2012;38(1): 7–15
- 17 Kadir RA, McLintock C. Thrombocytopenia and disorders of platelet function in pregnancy. *Semin Thromb Hemost* 2011;37(6): 640–652
- 18 Tan CW, Ward CM, Morel-Kopp MC. Evaluating heparin-induced thrombocytopenia: the old and the new. *Semin Thromb Hemost* 2012;38(2):135–143
- 19 Breakey VR, Blanchette VS. Childhood immune thrombocytopenia: a changing therapeutic landscape. *Semin Thromb Hemost* 2011;37(7):745–755

- 20 Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. *Semin Thromb Hemost* 2010;36(8):807–818
- 21 Jayandharan GR, Srivastava A, Srivastava A. Role of molecular genetics in hemophilia: from diagnosis to therapy. *Semin Thromb Hemost* 2012;38(1):64–78
- 22 Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: Part I—acquired hemophilia A. *Semin Thromb Hemost* 2012;38(5):433–446
- 23 Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. *Semin Thromb Hemost* 2012;38(7):673–682
- 24 Pels SG. Current therapies in primary immune thrombocytopenia. *Semin Thromb Hemost* 2011;37(6):621–630
- 25 Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. *Semin Thromb Hemost* 2012;38(5):483–496
- 26 Szántó T, Joutsu-Korhonen L, Deckmyn H, Lassila R. New insights into von Willebrand disease and platelet function. *Semin Thromb Hemost* 2012;38(1):55–63
- 27 Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. *Semin Thromb Hemost* 2012;38(4):305–321
- 28 Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. *Semin Thromb Hemost* 2012;38(1):16–22
- 29 Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. *Semin Thromb Hemost* 2012;38(2):178–184
- 30 Favaloro EJ, Wong RC. The antiphospholipid syndrome: diagnosis, pathogenesis, laboratory testing, and management. *Semin Thromb Hemost* 2012;38(4):299–304
- 31 Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. *Semin Thromb Hemost* 2012;38(1):79–94
- 32 Linden MD, Tran H, Woods R, Tonkin A. High platelet reactivity and antiplatelet therapy resistance. *Semin Thromb Hemost* 2012;38(2):200–212
- 33 Coppola A, Tufano A, Di Capua M, Franchini M. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. *Semin Thromb Hemost* 2011;37(8):929–945
- 34 Montagnana M, Favaloro EJ, Lippi G. Coffee intake and cardiovascular disease: virtue does not take center stage. *Semin Thromb Hemost* 2012;38(2):164–177
- 35 Tsai HM. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. *Semin Thromb Hemost* 2012;38(5):469–482
- 36 Scharf RE. Drugs that affect platelet function. *Semin Thromb Hemost* 2012;38(8):865–883
- 37 Galli M. Interpretation and recommended testing for antiphospholipid antibodies. *Semin Thromb Hemost* 2012;38(4):348–352
- 38 Zoellner H. Dental infection and vascular disease. *Semin Thromb Hemost* 2011;37(3):181–192
- 39 Lippi G, Favaloro EJ, Cervellini G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. *Semin Thromb Hemost* 2011;37(3):237–251
- 40 Franchini M, Lippi G, Favaloro EJ. Acquired inhibitors of coagulation factors: part II. *Semin Thromb Hemost* 2012;38(5):447–453
- 41 Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. *Semin Thromb Hemost* 2013;39(2):117–126
- 42 Adams M. Tissue factor pathway inhibitor: new insights into an old inhibitor. *Semin Thromb Hemost* 2012;38(2):129–134
- 43 Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. *Semin Thromb Hemost* 2012;38(4):339–347
- 44 Köse O, Zimmerhackl LB, Jungtraithmayr T, Mache C, Nürnberger J. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. *Semin Thromb Hemost* 2010;36(6):669–672
- 45 Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. *Semin Thromb Hemost* 2012;38(4):333–338
- 46 De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. *Semin Thromb Hemost* 2011;37(3):226–236
- 47 Thom KE, Hanslik A, Male C. Anticoagulation in children undergoing cardiac surgery. *Semin Thromb Hemost* 2011;37(7):826–833
- 48 Bitzan M, Schaefer F, Reymond D. Treatment of typical (enteropathic) hemolytic uremic syndrome. *Semin Thromb Hemost* 2010;36(6):594–610
- 49 Flaumenhaft R, Mairuhu AT, Italiano JE. Platelet- and megakaryocyte-derived microparticles. *Semin Thromb Hemost* 2010;36(8):881–887
- 50 Ranucci M, Baryshnikova E, Colella D. Monitoring prohemostatic treatment in bleeding patients. *Semin Thromb Hemost* 2012;38(3):282–291
- 51 Favaloro EJ. Clinical utility of the PFA-100. *Semin Thromb Hemost* 2008;34(8):709–733
- 52 Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. *Semin Thromb Hemost* 2012;38(1):31–37
- 53 Toriello HV. Thrombocytopenia-absent radius syndrome. *Semin Thromb Hemost* 2011;37(6):707–712
- 54 Schroeder V, Kohler HP. Factor XIII deficiency: an update. *Semin Thromb Hemost* 2013;39(6):632–641
- 55 Kuperman AA, Kenet G, Papadakis E, Brenner B. Intraventricular hemorrhage in preterm infants: coagulation perspectives. *Semin Thromb Hemost* 2011;37(7):730–736
- 56 Heleen van Ommen C, Middeldorp S. Thrombophilia in childhood: to test or not to test. *Semin Thromb Hemost* 2011;37(7):794–801
- 57 Darvish-Kazem S, Douketis JD. Perioperative management of patients having noncardiac surgery who are receiving anticoagulant or antiplatelet therapy: an evidence-based but practical approach. *Semin Thromb Hemost* 2012;38(7):652–660
- 58 Franchini M, Vescovi PP, Garofano M, Veneri D. *Helicobacter pylori*-associated idiopathic thrombocytopenic purpura: a narrative review. *Semin Thromb Hemost* 2012;38(5):463–468
- 59 Hellgren M. Hemostasis during normal pregnancy and puerperium. *Semin Thromb Hemost* 2003;29(2):125–130
- 60 Salmela B, Joutsu-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. *Semin Thromb Hemost* 2012;38(1):23–30
- 61 Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox”. *Semin Thromb Hemost* 2010;36(1):59–70
- 62 Rak J. Microparticles in cancer. *Semin Thromb Hemost* 2010;36(8):888–906
- 63 Jurk K, Kehrel BE. Platelets: physiology and biochemistry. *Semin Thromb Hemost* 2005;31(4):381–392
- 64 Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. *Semin Thromb Hemost* 2011;37(3):267–274
- 65 Mariani G, Bernardi F. Factor VII deficiency. *Semin Thromb Hemost* 2009;35(4):400–406
- 66 Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. *Semin Thromb Hemost* 2011;37(3):280–297